COMMUNIQUÉS West-GlobeNewswire

Alignment Healthcare Reports Fourth Quarter and Full-Year 2024 Results; Provides Full-Year 2025 Financial Guidance

27/02/2025 - 22:01

Reports 189,100 health plan members as of Dec. 31, 2024, up 58.6% year-over-year, beating year-end expectations Achieves first full year of positive adjusted EBITDA as a public company, driven by operating leverage and [...]

Amedisys Reports Fourth Quarter and Year End 2024 Financial Results

26/02/2025 - 22:30

BATON ROUGE, La., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three-month period and year ended December 31, 2024. Three-Month Periods Ended December 31, [...]

Rapid Micro Biosystems to Participate in Upcoming Investor Conferences

26/02/2025 - 22:15

LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]

Certara Reports Fourth Quarter 2024 Financial Results

26/02/2025 - 22:15

Issues Full Year 2025 Financial Guidance RADNOR, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the [...]

Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

26/02/2025 - 22:13

Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance Q4 2024 Net Product Revenue of $141.8 Million [...]

Teladoc Health Reports Full Year and Fourth Quarter 2024 Results

26/02/2025 - 22:05

PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 (“Full Year [...]

Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference

26/02/2025 - 22:05

BRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical [...]

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

26/02/2025 - 22:05

Conference call to provide corporate updates today at 4:30 pm ET 2024 revenues of $286M, +43% v. 2023; 4Q 2024 revenues of $77M, +31% v. 4Q 2023 2024 net income of $28M; Non-GAAP net income of $68M 4Q 2024 net income of [...]

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

26/02/2025 - 22:05

Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer Presented interim data for RLY-2608 + [...]

Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)

26/02/2025 - 22:05

FOSTER CITY, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product [...]

Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

26/02/2025 - 22:05

CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company [...]

Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

26/02/2025 - 22:03

– KOMET-001 registrational trial in R/R NPM1 -mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential [...]

Health Catalyst Reports Fourth Quarter and Year End 2024 Results

26/02/2025 - 22:03

SALT LAKE CITY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported [...]

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

26/02/2025 - 22:02

Company anticipates substantially completing enrollment this year in ongoing Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer to enable expected data readout in 2026 Company [...]

scPharmaceuticals Announces Participation in Two Upcoming Investor Conferences

26/02/2025 - 22:01

BURLINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric [...]

MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results

26/02/2025 - 22:01

Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05 , Respectively Fourth Quarter Adjusted EBITDA¹ was $20 [...]

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

26/02/2025 - 22:01

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended [...]

Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

26/02/2025 - 22:01

LEXINGTON, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]

Inventiva announces the publication in Biomedicine & Pharmacotherapy of the results from a preclinical study showing improvement of portal hypertension with lanifibranor treatment

26/02/2025 - 22:00

The study demonstrated that lanifibranor improved Portal Hypertension (PH) in mouse models of fibrotic PH and prehepatic non-fibrotic PH Lanifibranor was observed to decrease portal pressure by improving Liver [...]